|
rs10033900
|
|
|
0.840 |
GeneticVariation |
BEFREE |
Con-clusion: CFI rs10033900 and rs2285714 polymorphisms in a Turkish population were not associated with AMD.
|
31614353 |
2019 |
|
rs10033900
|
|
|
0.840 |
GeneticVariation |
BEFREE |
To determine the impact of <i>HTRA1</i> rs1120638, <i>TIMP3</i> rs9621532, <i>VEGFA</i> rs833068, <i>CFI</i> rs10033900, <i>ERCC6</i> rs3793784, and <i>KCTD10</i> rs56209061 genotypes on the development of age-related macular degeneration (AMD) in the Lithuanian population.
|
31583032 |
2019 |
|
rs10033900
|
|
|
0.840 |
GeneticVariation |
GWASCAT |
A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants.
|
26691988 |
2016 |
|
rs10033900
|
|
T |
0.840 |
GeneticVariation |
GWASDB |
Heritability and genome-wide association study to assess genetic differences between advanced age-related macular degeneration subtypes.
|
22705344 |
2012 |
|
rs10033900
|
|
T |
0.840 |
GeneticVariation |
GWASDB |
Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration.
|
21665990 |
2011 |
|
rs10033900
|
|
T |
0.840 |
GeneticVariation |
GWASCAT |
Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration.
|
21665990 |
2011 |
|
rs10033900
|
|
|
0.840 |
GeneticVariation |
BEFREE |
Individuals with the homozygous CFI rs10033900 TT genotype had a 2.9 [1.2-7.2]-fold increased risk, and those with the CFH Y402H GG genotype had a 2.2 [1.0-4.8]-fold higher risk of developing AMD compared with non-carriers.
|
21906714 |
2011 |
|
rs10033900
|
|
|
0.840 |
GeneticVariation |
GWASCAT |
Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC).
|
20385826 |
2010 |
|
rs10033900
|
|
|
0.840 |
GeneticVariation |
BEFREE |
There was a possible association between LIPC and complement factor H (CFH) rs1410996, and a possible interaction effect between LIPC and both CFH rs10033900 and the complement factor I (CFI) variants in terms of risk of AMD.
|
21139980 |
2010 |
|
rs10033900
|
|
|
0.840 |
GeneticVariation |
GWASDB |
Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC).
|
20385826 |
2010 |
|
rs141853578
|
|
|
0.750 |
GeneticVariation |
BEFREE |
Current study showed that CFI rs141853578 (G119R) is a risk factor for developing advanced type AMD.
|
29392637 |
2019 |
|
rs141853578
|
|
|
0.750 |
GeneticVariation |
BEFREE |
We explored the occurrence of seven rare variants independently associated with AMD (<i>CFH</i> rs121913059 (p.Arg1210Cys), <i>CFI</i> rs141853578 (p.Gly119Arg), <i>C3</i> rs147859257 (p.Lys155Gln), and <i>C9</i> rs34882957 (p.Pro167Ser)) and three non-coding variants in or near the <i>CFH</i> gene (rs148553336, rs35292876, and rs191281603) in 24 AMD case-control studies.
|
29410599 |
2018 |
|
rs141853578
|
|
|
0.750 |
GeneticVariation |
BEFREE |
Carriers of CFH (Arg175Gln and Ser193Leu) and CFI (Gly119Arg and Leu131Arg) variants have an impaired ability to regulate complement activation and may benefit more from complement-inhibiting therapy than patients with AMD in general.
|
27918759 |
2017 |
|
rs141853578
|
|
|
0.750 |
GeneticVariation |
GWASCAT |
A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants.
|
26691988 |
2016 |
|
rs141853578
|
|
|
0.750 |
GeneticVariation |
BEFREE |
Although these data support the conclusions of van de Ven et al. that the p.Gly119Arg substitution confers a high risk of AMD, our data suggest that this missense mutation is not as rare or as highly penetrant as previously reported.
|
25352734 |
2014 |
|
rs141853578
|
|
|
0.750 |
GeneticVariation |
BEFREE |
Here, we report the identification of a rare, highly penetrant missense mutation in CFI encoding a p.Gly119Arg substitution that confers high risk of AMD (P = 3.79 × 10⁻⁶; odds ratio (OR) = 22.20, 95% confidence interval (CI) = 2.98-164.49).
|
23685748 |
2013 |
|
rs1435946585
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Carriers of CFH (Arg175Gln and Ser193Leu) and CFI (Gly119Arg and Leu131Arg) variants have an impaired ability to regulate complement activation and may benefit more from complement-inhibiting therapy than patients with AMD in general.
|
27918759 |
2017 |
|
rs1486838526
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Carriers of CFH (Arg175Gln and Ser193Leu) and CFI (Gly119Arg and Leu131Arg) variants have an impaired ability to regulate complement activation and may benefit more from complement-inhibiting therapy than patients with AMD in general.
|
27918759 |
2017 |